# Vincristine (Catharanthus roseus alkaloid)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/vincristine-catharanthus-roseus-alkaloid
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Vincristine (Catharanthus roseus-derived vinca alkaloid), Marqibo (liposomal form), Vincristine sulfate, Oncovin, Catharanthus roseus alkaloid, Vincristine (Catharanthus roseus), VCR, Leurocristine

## Overview

Vincristine is a vinca alkaloid that binds tubulin beta chain (TUBB, UniProt P07437) and alpha-tubulin subunits, inhibiting microtubule polymerization and arresting rapidly dividing cells in metaphase, ultimately triggering apoptosis. It is an FDA-approved intravenous chemotherapeutic agent administered at 1–1.4 mg/m² IV every three weeks, with documented clinical efficacy across acute lymphoblastic leukemia, non-Hodgkin lymphoma, Wilms tumor, and glioblastoma in combination regimens.

## Health Benefits

- **Antimitotic Activity in Hematologic Malignancies**: Vincristine disrupts the mitotic spindle by binding beta-tubulin, inducing metaphase arrest and apoptosis in lymphocytic leukemia and lymphoma cells; it forms the backbone of CHOP and MOPP regimens used in non-Hodgkin lymphoma treatment.
- **Efficacy in Pediatric Acute Lymphoblastic Leukemia (ALL)**: Vincristine is a cornerstone drug in ALL induction therapy, contributing to remission rates exceeding 90% in pediatric protocols when combined with corticosteroids and asparaginase.
- **Activity Against Solid Tumors**: Vincristine demonstrates cytotoxic activity against glioblastomas, Wilms tumor, rhabdomyosarcoma, and small cell lung cancer by halting division of rapidly proliferating tumor cells through microtubule depolymerization.
- **Disruption of Intracellular Transport in Tumor Cells**: Beyond mitosis, vincristine disrupts microtubule-dependent intracellular transport, interfering with amino acid [metabolism](/ingredients/condition/weight-management), cyclic AMP signaling, and [glutathione](/ingredients/condition/detox) utilization specifically in malignant cells.
- **Liposomal Formulation Enhances Therapeutic Index**: Liposomal encapsulation of vincristine (vincristine sulfate liposome injection, VSLI) improves plasma concentration, prolongs circulation time, and reduces peripheral neurotoxicity compared to conventional formulations, expanding its clinical utility.
- **Calmodulin and Ca²⁺-ATPase Inhibition**: Vincristine inhibits calmodulin-dependent Ca²⁺-ATPase and disrupts cellular respiration and nucleic acid biosynthesis in tumor cells, providing multimechanistic cytotoxic activity beyond pure antimitotic effects.
- **Combination Synergy in Multi-Drug Regimens**: When combined with agents such as doxorubicin, cyclophosphamide, and prednisone, vincristine contributes mechanistically distinct cell-cycle disruption that enhances overall tumor response rates and reduces emergence of drug resistance.

## Mechanism of Action

Vincristine binds with high affinity to tubulin heterodimers at the vinca domain on beta-tubulin (TUBB, UniProt P07437) and alpha-tubulin-4A, suppressing dynamic instability at microtubule plus ends during the M and S phases of the cell cycle; at low concentrations it reduces microtubule dynamicity without full depolymerization, while at higher concentrations it causes complete spindle disassembly and mitotic arrest at metaphase. The resulting failure of chromatid separation triggers the spindle assembly checkpoint and activates intrinsic apoptotic pathways, selectively eliminating rapidly dividing cells. Beyond its antimitotic role, vincristine disrupts microtubule-dependent axonal transport in neurons (accounting for its dose-limiting peripheral neurotoxicity), and additionally interferes with calmodulin-dependent Ca²⁺-ATPase activity, cyclic AMP [metabolism](/ingredients/condition/weight-management), [glutathione](/ingredients/condition/detox) homeostasis, nucleic acid and lipid biosynthesis, and leukocyte production. Hepatic metabolism proceeds primarily through CYP3A4, CYP3A5, and CYP3A7 enzymes, with CYP3A5 genetic polymorphisms contributing to the wide interpatient pharmacokinetic variability observed clinically.

## Clinical Summary

Pivotal clinical evidence for vincristine comes primarily from large cooperative oncology group trials, including Children's Oncology Group and ECOG studies, where it is consistently evaluated as part of induction and consolidation regimens for ALL and aggressive lymphomas rather than as a standalone agent. In the CHOP regimen for diffuse large B-cell lymphoma, combination therapy including vincristine at 1.4 mg/m² (capped at 2 mg) achieves complete response rates of approximately 60–70% in eligible patients. The FDA-approved liposomal vincristine sulfate formulation demonstrated an objective response rate of 26% (complete remission plus complete remission with incomplete count recovery) in a Phase II trial of relapsed/refractory Philadelphia chromosome-negative adult ALL patients who had received two or more prior lines of therapy. Confidence in vincristine's efficacy for its approved indications is high given the volume and consistency of evidence, though its toxicity profile, particularly dose-limiting peripheral neuropathy, constrains dose optimization in clinical practice.

## Nutritional Profile

Vincristine is not a nutritional compound and has no meaningful macronutrient, micronutrient, or dietary phytochemical profile relevant to human nutrition. As a pharmaceutical alkaloid present at less than 0.0003% dry weight in Catharanthus roseus leaf tissue, it does not constitute a dietary component of any food source and is not consumed through diet. The compound's molecular weight is 824.972 Da (average), molecular formula C₄₆H₅₆N₄O₁₀, and it possesses a complex terpenoid indole alkaloid scaffold formed by the enzymatic coupling of the monomeric precursors vindoline and catharanthine. Bioavailability from any oral route is negligible and clinically irrelevant; systemic exposure is achieved exclusively via intravenous administration.

## Dosage & Preparation

- **Intravenous Solution (Conventional)**: 1.0–1.4 mg/m² IV bolus every 3 weeks; many protocols cap the absolute dose at 2 mg per administration to limit cumulative neurotoxicity.
- **Liposomal Intravenous Formulation (VSLI/Marqibo)**: 2.25 mg/m² IV over 1 hour weekly for relapsed/refractory ALL; no dose cap applied due to altered pharmacokinetics with liposomal encapsulation.
- **Oral Administration**: Not used clinically due to negligible oral bioavailability and unacceptable systemic toxicity; vincristine is never administered orally.
- **Intrathecal Administration**: Absolutely contraindicated — intrathecal administration is universally fatal and represents a critical medication safety concern.
- **Timing and Cycle Structure**: Typically administered on Day 1 of multi-week chemotherapy cycles; precise scheduling within combination regimens (e.g., CHOP Day 1, ALL induction Day 1/8/15/22) is protocol-specific.
- **Standardization**: Pharmaceutical-grade vincristine sulfate is used at defined concentrations (1 mg/mL solution); no standardization in the herbal or dietary supplement sense applies.
- **No Supplemental Form Exists**: Vincristine is not available as a dietary supplement, nutraceutical, or over-the-counter product in any jurisdiction.

## Safety & Drug Interactions

Vincristine carries a well-characterized and serious toxicity profile; dose-limiting toxicity is peripheral sensorimotor neuropathy resulting from disruption of microtubule-dependent axonal transport, manifesting as paresthesia, foot drop, cranial nerve palsies, and autonomic dysfunction, with cumulative dose being the primary risk determinant. Myelosuppression, immunosuppression, constipation (autonomic neuropathy), syndrome of inappropriate antidiuretic hormone secretion (SIADH), and alopecia are additional documented adverse effects. Critical drug interactions include CYP3A4/5 inhibitors (e.g., azole antifungals, abametapir, certain HIV protease inhibitors) which increase vincristine exposure and neurotoxicity risk, and CYP3A inducers (e.g., phenobarbital, rifampin) which accelerate clearance and may reduce efficacy. Vincristine is classified FDA Pregnancy Category D (evidence of fetal risk); it is contraindicated in patients with the demyelinating form of Charcot-Marie-Tooth disease, and intrathecal administration is absolutely and fatally contraindicated — a black box warning exists requiring dispensing in minibags to prevent inadvertent intrathecal injection.

## Scientific Research

Vincristine carries one of the strongest evidence bases among oncology drugs, supported by decades of Phase II and Phase III randomized controlled trials as part of established multi-agent chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for non-Hodgkin lymphoma and BFM-based protocols for pediatric ALL, with pediatric ALL remission induction rates documented above 90% in large cooperative group studies. Pharmacokinetic characterization across human subjects demonstrates a tri-exponential IV disposition profile with half-life ranging 155–1500 minutes, volume of distribution 57–420 L/m², and clearance 82–482 mL/min/m², reflecting extensive tissue binding (>90% tissue-bound within 15–30 minutes of infusion). The liposomal formulation (VSLI; Marqibo) received FDA accelerated approval based on a single-arm Phase II trial demonstrating a 26% overall response rate in heavily pretreated Philadelphia chromosome-negative ALL patients. Evidence quality is high for hematologic malignancy indications given decades of multicenter RCT data, though vincristine is evaluated exclusively as a component of combination regimens rather than as monotherapy in most pivotal trials.

## Historical & Cultural Context

Catharanthus roseus, the source plant, was used in traditional folk medicine systems across Madagascar, India, South Africa, and the Caribbean primarily for the management of diabetes, with hypoglycemic activity documented in preclinical studies, and not historically for any oncological purpose. In the 1950s, researchers at Eli Lilly and Company (Robert Noble and Charles Beer in Canada, and Gordon Svoboda at Eli Lilly) independently investigated C. roseus extracts based on ethnobotanical reports of antidiabetic use, leading to the serendipitous discovery of potent myelosuppressive and antitumor alkaloids including vincristine and vinblastine. Vincristine received FDA approval in 1963, making it one of the earliest plant-derived chemotherapeutic agents to reach clinical medicine and establishing the Madagascar periwinkle as one of the most pharmacologically significant medicinal plants in modern oncology. Its discovery catalyzed the field of natural product anticancer drug discovery and directly influenced subsequent research programs that yielded paclitaxel (from Taxus brevifolia) and other plant-derived cytotoxics.

## Synergistic Combinations

Vincristine demonstrates well-established pharmacological synergy with corticosteroids (dexamethasone, prednisone) in ALL and lymphoma treatment, where glucocorticoid-mediated upregulation of apoptotic pathways complements vincristine-induced mitotic arrest, forming the mechanistic rationale for the VCR-steroid backbone of virtually all ALL induction protocols. In the CHOP regimen, vincristine acts synergistically with doxorubicin (topoisomerase II inhibition, DNA intercalation) and cyclophosphamide (DNA alkylation) by targeting cell-cycle progression at complementary points, reducing the probability of clonal resistance emergence. Liposomal co-encapsulation or nanoparticle co-delivery strategies pairing vincristine with doxorubicin or cytarabine have shown enhanced intratumoral drug accumulation and improved therapeutic indices in preclinical models relative to free drug combinations.

## Frequently Asked Questions

### How does vincristine work to kill cancer cells?

Vincristine binds to beta-tubulin and alpha-tubulin subunits at the vinca binding domain, preventing microtubule polymerization and arresting cancer cells in the metaphase stage of mitosis. This spindle assembly failure triggers the intrinsic apoptotic cascade, selectively eliminating rapidly dividing malignant cells; at low concentrations it suppresses microtubule dynamic instability, while higher concentrations cause complete spindle depolymerization and cell death.

### What cancers is vincristine used to treat?

Vincristine is FDA-approved and clinically used in the treatment of acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (as part of CHOP), Hodgkin lymphoma (MOPP/BEACOPP), Wilms tumor, rhabdomyosarcoma, neuroblastoma, and glioblastoma multiforme. It is almost always administered as a component of multi-agent chemotherapy regimens rather than as monotherapy, contributing mechanistically distinct antimitotic activity to combination protocols.

### What are the main side effects of vincristine?

The dose-limiting toxicity of vincristine is peripheral neuropathy, which results from disruption of microtubule-dependent axonal transport in neurons and manifests as tingling, numbness, foot drop, weakness, and autonomic dysfunction including severe constipation. Other significant side effects include alopecia, myelosuppression, SIADH (causing hyponatremia), and immunosuppression; neurotoxicity is cumulative and may not be fully reversible after treatment discontinuation.

### What is the standard dose of vincristine?

The standard clinical dose of vincristine sulfate is 1.0–1.4 mg/m² administered as an intravenous bolus every three weeks, with most oncology protocols applying an absolute dose cap of 2 mg per administration to limit cumulative neurotoxicity. The liposomal formulation (Marqibo/VSLI) is dosed at 2.25 mg/m² IV over one hour weekly without a dose cap, as its altered pharmacokinetics reduce peak plasma neurotoxic exposure; vincristine has no oral supplemental form.

### Can vincristine be given intrathecally or orally?

Intrathecal administration of vincristine is absolutely contraindicated and invariably fatal due to ascending myeloencephalopathy; this represents one of the most critical medication safety warnings in oncology, and regulatory bodies mandate dispensing vincristine in minibags rather than syringes to physically prevent intrathecal administration. Oral administration is not clinically used because vincristine has negligible oral bioavailability and would cause unacceptable systemic toxicity without meaningful antitumor exposure; all clinical use is exclusively intravenous.

### Is vincristine safe for children with acute lymphoblastic leukemia?

Vincristine is a cornerstone drug in pediatric acute lymphoblastic leukemia (ALL) treatment and is considered essential in standard chemotherapy regimens for children. However, it carries serious side effects including peripheral neuropathy and requires careful dose management based on body surface area, close monitoring during treatment, and specialized oncology care. Children receiving vincristine need regular assessment for neurotoxicity and other adverse effects by experienced hematologic-oncology teams.

### Does vincristine interact with other chemotherapy drugs?

Vincristine is routinely combined with other chemotherapy agents in established regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and MOPP (mechlorethamine, vincristine, procarbazine, prednisone) for lymphoma treatment. These combinations are designed to work synergistically and are used under strict oncology protocols; however, concurrent use with other medications should only be managed by oncology specialists to avoid dangerous interactions and overlapping toxicities.

### Why is vincristine more effective in lymphomas and leukemias than other cancer types?

Vincristine's mechanism of binding beta-tubulin and disrupting the mitotic spindle is particularly effective against rapidly dividing lymphoid cells, making it highly efficacious in acute lymphoblastic leukemia, non-Hodgkin lymphoma, and other hematologic malignancies. Solid tumors often develop resistance to vincristine through mechanisms such as increased drug efflux pumps, which is why it is not a standard treatment for most solid cancers. Its selectivity and proven efficacy in blood cancers make it a preferred agent in first-line regimens for these hematologic malignancies.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*